ATHX - Athersys, Inc.
Athersys, Inc., is a biopharmaceutical company engaged in the discovery and development of therapeutic products. Through the application of its technologies, the Company has established a pipeline of therapeutic product development programs in multiple disease areas. The Company's current product development portfolio consists of MultiStem, a patented and stem cell product that the Company is developing as a treatment for multiple disease indications, and that is being evaluated in two ongoing clinical trials. In addition, the Company are developing novel pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy or other forms of excessive daytime sleepiness. In December 2008, the Company were granted authorization by the United States Food and Drug Administration (FDA), to initiate a third clinical trial, administering MultiStem for the treatment of ischemic stroke.
The Aroon technical indicator is quite new and was developed by Tushar Chande in 1995. Similar to the MACD, it is used for identifying trends in an underlying security and tries to determine what the chances are that the trends will reverse. The indicator is made up of two lines: The first line is called the Aroon Up, which measures the strength of the uptrend. The second line is called the Aroon Down, and it conversely measures the strength of a downtrend. The Aroon indicator reports the time it is taking for the price to reach the highest or lowest points over a given period of time, each reported as a percentage of total time. The Aroon up as well as the Aroon Down fluctuate between zero and 100, and values close to 100 indicate a very strong trend, while zero indicates a weak trend. The main assumption underlying this indicator is that a stock's price will close at record highs in an uptrend, and record lows in a downtrend.
bgamall
TVN_Patrick
DontTakeLosses
Reply!
Retweet!